BCBS Florida Medical Policy Updates – June 2018

Click here to view the Florida Blue Cross Blue Shield Medical Policy Updates »

June 2018 Medical Policy Updates:

• Advanced Imaging of the Heart-Echocardiography
• Apalutamide (Erleada)
• Arterial Ultrasound (Duplex Ultrasounds and Physiologic Testing)
• Benralizumab (Fasenra)
• Bezlotoxumab (Zinplava) Injection
• Buprenorphine HCl (Probuphine ®) Subdermal Implant
• Burosumab (Crysvita)
• CGRP Inhibitors
• Cobimetinib (Cotellic) Tablet
• Computed Tomography (CT) Abdomen and Pelvis
• Computed Tomography to Detect Coronary Artery Calcification
• Cranial Orthosis as a Treatment for Plagiocephaly
• Cranial Orthosis for Craniosynostoses and Plagiocephaly
• Dabrafenib (Tafinlar®) Capsules
• Deep Brain Stimulation and Responsive Neurostimulation
• Diagnostic Coronary Angiography
• DME Attached Table
• Drugs and Biologics without Medical Coverage Guideline
• Elective Percutaneous Coronary Intervention
• Extracorporeal Membrane Oxygenation (ECMO) for Adult Conditions
• Fosnetupitant-Palonosetron (Akynzeo) IV
• Fostamatinib (Tavalisse)
• Functional Magnetic Resonance Imaging (fMRI)
• Granulocyte Colony Stimulating Factors
• Interspinous and Interlaminar Stabilization Distraction and Fixation Devices
• Investigational Services
• Ipilimumab (Yervoy TM) Injection
• KRAS, NRAS, and BRAF Mutation Analysis in Metastatic Colorectal Cancer
• KRAS, NRAS, and BRAF Mutation Variant Analysis in Metastatic Colorectal Cancer
• Lanreotide (Somatuline® Depot) Injection
• Lower Limb Microprocessor-Controlled Prosthetics
• Magnetic Resonance Imaging of the Breast
• Magnetic Resonance Spectroscopy (MRS)
• Mechanical Stretching Devices
• Minimally Invasive Fusion Techniques
• Nivolumab (Opdivo)
• Octreotide Acetate (Sandostatin LAR® Depot) Injection
• Pembrolizumab (Keytruda®) Injection
• Percutaneous Tibial Nerve Stimulation
• Percutaneous Vertebroplasty, Kyphoplasty, and Sacroplasty
• Pneumatic Compression Devices
• Quantitative Sensory Testing
• Speech Therapy Services
• Technologies for Evaluating Skin Lesions Suspected of Malignancy
• Technologies for the Evaluation of Malignant Melanoma
• Tezacaftor-Ivacaftor (Symdeko)
• Tildrakizumab-asmn (Ilumya)
• Trametinib (Mekinist TM) Tablets
• Transcatheter Aortic Valve Replacement
• Transmyocardial Revascularization (TMR)
• Trastuzumab (Herceptin®) Injection
• Vemurafenib (Zelboraf TM)
• Vestibular Rehabilitation
• Viscocanalostomy and Canaloplasty

Click here to view the Florida Blue Cross Blue Shield Medical Policy Updates »

Policy Alerts monitors Commercial and Medicare medical policies for changes. While medical Insurance carriers typically update medical policies annually, there are many reasons why they might review or update a policy. When reviews occur out of cycle they often go unnoticed. Policy Alerts keeps you updated when Payers make coverage changes to medical policies affecting your business.

Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on medical Insurance decisions in real-time. When changes occur, instant email alerts are delivered to your inbox. Clients have access to detailed coverage reports and medical policies through the interactive Policy Alerts Dashboard portal. Save time each month and keep focused on important Payer medical policy reviews and coverage decisions affecting your business!

Policy Alerts takes a client-focused hands-on approach and is constantly working to provide our customers with helpful insights and actionable analytics. We understand what our clients need and are dedicated to providing timely, accurate, and always up-to-date reports.

Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.